KR20240105380A - Psma 항원을 표적으로 하는 리간드 화합물, 이의 킬레이트 및 전립선암의 진단 및 치료를 위한 이의 응용 - Google Patents
Psma 항원을 표적으로 하는 리간드 화합물, 이의 킬레이트 및 전립선암의 진단 및 치료를 위한 이의 응용 Download PDFInfo
- Publication number
- KR20240105380A KR20240105380A KR1020247014634A KR20247014634A KR20240105380A KR 20240105380 A KR20240105380 A KR 20240105380A KR 1020247014634 A KR1020247014634 A KR 1020247014634A KR 20247014634 A KR20247014634 A KR 20247014634A KR 20240105380 A KR20240105380 A KR 20240105380A
- Authority
- KR
- South Korea
- Prior art keywords
- psma
- ligand compound
- pharmaceutically acceptable
- integer
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111329108.1 | 2021-11-10 | ||
| CN202111329108 | 2021-11-10 | ||
| PCT/CN2022/130833 WO2023083209A1 (zh) | 2021-11-10 | 2022-11-09 | 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240105380A true KR20240105380A (ko) | 2024-07-05 |
Family
ID=86335105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247014634A Pending KR20240105380A (ko) | 2021-11-10 | 2022-11-09 | Psma 항원을 표적으로 하는 리간드 화합물, 이의 킬레이트 및 전립선암의 진단 및 치료를 위한 이의 응용 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260069725A1 (https=) |
| EP (1) | EP4431503A1 (https=) |
| JP (1) | JP2024544870A (https=) |
| KR (1) | KR20240105380A (https=) |
| CN (1) | CN118176188A (https=) |
| AU (1) | AU2022384375A1 (https=) |
| CA (1) | CA3237743A1 (https=) |
| TW (1) | TW202321204A (https=) |
| WO (1) | WO2023083209A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118852044A (zh) | 2021-09-03 | 2024-10-29 | 晶核生物医药科技(南京)有限公司 | 一种肽脲素衍生物、含其的药物组合物及其应用 |
| CN117069670B (zh) * | 2023-07-31 | 2026-04-10 | 复旦大学附属华山医院 | 靶向psma的二聚体化合物及其衍生物和应用 |
| CN119954773A (zh) * | 2023-10-31 | 2025-05-09 | 苏州威智创科生物有限公司 | Psma化合物、包含其的药物组合物及其用途 |
| WO2025167998A1 (zh) * | 2024-02-06 | 2025-08-14 | 北京昌平实验室 | 膦酸酯骨架的psma靶向偶联物 |
| CN118221764A (zh) * | 2024-03-05 | 2024-06-21 | 苏州大学 | 一种双靶向分子探针及其制备方法与应用 |
| WO2026002208A1 (zh) * | 2024-06-28 | 2026-01-02 | 思路迪生物医药(上海)有限公司 | 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629201B2 (en) * | 2017-05-24 | 2023-04-18 | ITM Isotope Technologies Munich SE | PSMA-binding agents and uses thereof |
| US20200339625A1 (en) * | 2017-10-22 | 2020-10-29 | Provincial Health Services Authority | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
| CN114401947B (zh) * | 2019-06-21 | 2024-11-29 | 省卫生服务机构 | 靶向前列腺特异性膜抗原的放射性标记化合物 |
-
2022
- 2022-11-09 JP JP2024527096A patent/JP2024544870A/ja active Pending
- 2022-11-09 CA CA3237743A patent/CA3237743A1/en active Pending
- 2022-11-09 TW TW111142867A patent/TW202321204A/zh unknown
- 2022-11-09 US US18/708,905 patent/US20260069725A1/en active Pending
- 2022-11-09 AU AU2022384375A patent/AU2022384375A1/en active Pending
- 2022-11-09 CN CN202280074508.9A patent/CN118176188A/zh active Pending
- 2022-11-09 EP EP22892003.9A patent/EP4431503A1/en active Pending
- 2022-11-09 KR KR1020247014634A patent/KR20240105380A/ko active Pending
- 2022-11-09 WO PCT/CN2022/130833 patent/WO2023083209A1/zh not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024544870A (ja) | 2024-12-05 |
| AU2022384375A1 (en) | 2024-05-09 |
| CN118176188A (zh) | 2024-06-11 |
| EP4431503A1 (en) | 2024-09-18 |
| CA3237743A1 (en) | 2023-05-19 |
| TW202321204A (zh) | 2023-06-01 |
| US20260069725A1 (en) | 2026-03-12 |
| WO2023083209A1 (zh) | 2023-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20240105380A (ko) | Psma 항원을 표적으로 하는 리간드 화합물, 이의 킬레이트 및 전립선암의 진단 및 치료를 위한 이의 응용 | |
| US20250057993A1 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers | |
| CN102911256B (zh) | 一种放射性标记的多肽配合物及其制备方法和应用 | |
| CN118955478B (zh) | 谷氨酸尿素类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物 | |
| CN116514735B (zh) | 一种肽脲素衍生物、含其的药物组合物及其应用 | |
| CN114773433A (zh) | 一种cd25靶向多肽、分子探针及应用 | |
| CN115745903B (zh) | 一种肽脲素衍生物、含其的药物组合物及其应用 | |
| TWI893724B (zh) | 丹磺醯胺修飾的psma靶向化合物及其製備方法和應用 | |
| CN107308466B (zh) | 具有肿瘤血管靶向性的多肽、分子探针及其制备方法和应用 | |
| CN117586354A (zh) | 靶向gpc3多肽探针及其在制备诊疗放射性药物中的应用 | |
| JP2000507233A (ja) | 新規の三元複合体放射性薬剤 | |
| CN118666964A (zh) | 一种靶向肿瘤pd-l1的pet示踪剂、其标记前体、制备方法和应用 | |
| CN107674117B (zh) | Cu-64 标记的Dimer-San A环肽衍生物胰腺癌分子探针的制备方法 | |
| CN116763946B (zh) | 用于pd-l1靶向的环状多肽放射性药物及其制备方法和用途 | |
| CN116637211B (zh) | 一种sstr激动剂与抑制剂偶联的pet探针及其制备方法和应用 | |
| CN114685608B (zh) | 含有三硫醚键的环肽化合物或其衍生物、其合成方法和应用 | |
| RU2457215C1 (ru) | Октапептид для получения радиофармацевтических средств, радиофармацевтическое средство на его основе и способ диагностики опухолей, экспрессирующих соматостатиновые рецепторы | |
| CN119751415A (zh) | 双靶向PSMA和FAP-α的前列腺癌诊断或治疗放射性药物 | |
| KR101471891B1 (ko) | DOTA 표지 글루코사민-함유 시클로 RGDfK 유도체, 그 제조방법 및 그것을 포함하는 핵의학 영상 조영제 및 암 치료제 | |
| CN121270660A (zh) | D肽靶向肿瘤pd-l1的放射性诊疗药物及其标记前体、制备方法和应用 | |
| JP2015083546A (ja) | 癌の原発巣・骨転移の検査・治療用放射性標識薬剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |